US20110218478A1 - Methods and apparatus for reducing localized circulatory system pressure - Google Patents

Methods and apparatus for reducing localized circulatory system pressure Download PDF

Info

Publication number
US20110218478A1
US20110218478A1 US13107843 US201113107843A US2011218478A1 US 20110218478 A1 US20110218478 A1 US 20110218478A1 US 13107843 US13107843 US 13107843 US 201113107843 A US201113107843 A US 201113107843A US 2011218478 A1 US2011218478 A1 US 2011218478A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
valve
pressure
heart
shunt
implanting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US13107843
Other versions
US8328751B2 (en )
Inventor
Gad Keren
Randy Kesten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
V-WAVE Ltd
Original Assignee
LIBRA MEDICAL Inc
V-WAVE Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M27/00Drainage appliances for wounds or the like, i.e. wound drains, implanted drains
    • A61M27/002Implant devices for drainage of body fluids from one part of the body to another
    • A61M27/006Cerebrospinal drainage; Accessories therefor, e.g. valves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00234Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M27/00Drainage appliances for wounds or the like, i.e. wound drains, implanted drains
    • A61M27/002Implant devices for drainage of body fluids from one part of the body to another
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00234Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
    • A61B2017/00238Type of minimally invasive operation
    • A61B2017/00243Type of minimally invasive operation cardiac
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00234Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
    • A61B2017/00238Type of minimally invasive operation
    • A61B2017/00243Type of minimally invasive operation cardiac
    • A61B2017/00247Making holes in the wall of the heart, e.g. laser Myocardial revascularization
    • A61B2017/00252Making holes in the wall of the heart, e.g. laser Myocardial revascularization for by-pass connections, i.e. connections from heart chamber to blood vessel or from blood vessel to blood vessel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices
    • A61F2/2412Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices
    • A61F2/2493Transmyocardial revascularisation [TMR] devices
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/10Blood pumps; Artificial hearts; Devices for mechanical circulatory assistance, e.g. intra-aortic balloon pumps
    • A61M1/1008Tubes; Connections therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/10Blood pumps; Artificial hearts; Devices for mechanical circulatory assistance, e.g. intra-aortic balloon pumps
    • A61M1/101Non-positive displacement pumps, e.g. impeller, centrifugal, vane pumps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/10Blood pumps; Artificial hearts; Devices for mechanical circulatory assistance, e.g. intra-aortic balloon pumps
    • A61M1/1096Passive valves for blood pumps or artificial hearts, i.e. valves actuated by the fluid
    • A61M1/1098Valves having flexible or resilient parts, e.g. flap valve
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/10Blood pumps; Artificial hearts; Devices for mechanical circulatory assistance, e.g. intra-aortic balloon pumps
    • A61M1/12Blood pumps; Artificial hearts; Devices for mechanical circulatory assistance, e.g. intra-aortic balloon pumps implantable into the body
    • A61M1/122Heart assist devices, i.e. for assisting an ailing heart, using additional pumping means in the blood circuit
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/10Blood pumps; Artificial hearts; Devices for mechanical circulatory assistance, e.g. intra-aortic balloon pumps
    • A61M1/12Blood pumps; Artificial hearts; Devices for mechanical circulatory assistance, e.g. intra-aortic balloon pumps implantable into the body
    • A61M1/125Blood pumps; Artificial hearts; Devices for mechanical circulatory assistance, e.g. intra-aortic balloon pumps implantable into the body intravascular, i.e. introduced or implanted in an existing blood vessel

Abstract

The present invention is thus directed to methods and apparatus for decreasing pressure in a first portion of a vessel of the cardiac structure of a patient by implanting a shunt communicating with an area outside said first portion, whereby a volume of blood sufficient to reduce pressure in said first portion is released. Preferably, the first portion comprises the left ventricle and the pressure reduced is the end diastolic pressure, which is accomplished by having the shunt communicate with the left ventricle so a small volume of blood is released from the left ventricle to reduce the end diastolic pressure. Most preferably, the shunt selectively permits flow when a pressure differential between the left ventricle and another chamber of a heart above a threshold pressure, whereby shunting is prevented during left ventricular systole, or, alternatively, selectively permits flow when a pressure differential between the left ventricle and another chamber of a heart is between a lower threshold and a higher threshold, whereby shunting is again prevented during left ventricular systole. In certain embodiments a semi-passive check-valve is controlled and actuated by an external signal, either using a signal generated by an intra-corporeal electrical battery or an externally coupled energy source. In certain embodiments, the shunt has a pump with an input connected to the left ventricle, or other portion with excessive pressure, and an output connected to a volume of lower pressure. The preferred method of implanting the shunt to effect the present invention is by deploying a tubular element having two ends and a tissue affixation element disposed at each of said ends via a catheter, preferably, the fixation element is a shape retaining metallic material that returns to its original shape as part of the retention aspect of its function. In preferred embodiments of the apparatus, the tubular element is comprised of a biologically inert non-metallic material.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation under 35 U.S.C. § 120 of U.S. patent application Ser. No. 09/839,643, filed Apr. 20, 2001 and entitled “Methods and Apparatus for Reducing Localized Circulatory System Pressure,” the entire contents of which are incorporated herein by reference.
  • FIELD OF THE INVENTION
  • The present invention relates to treatments for reducing specific localized points of high pressure within the circulatory system, and more particularly to methods and apparatus to either acutely or chronically reduce left ventricular diastolic pressure that is created as a result of congestive heart failure or similar indications.
  • BACKGROUND OF THE INVENTION
  • Congestive heart failure (CHF) is recognized as the most common cause of hospitalization and mortality in Western society. CHF is an extremely serious affliction that has a great impact on the quality of life; it involves the loss of heart rate variability and rate responsive mechanisms in the heart, leading to impaired ventricular relaxation and low exercise tolerance. The disease afflicts about 4 million Americans in any given year; in the USA alone, there are annually about 400,000 new cases, 1 million hospital admissions, and $8 billion cost of care. Congestive heart failure is a syndrome characterized by left ventricular dysfunction, reduced exercise tolerance, impaired quality of life and dramatically shortened life expectancy. Decreased contractility of the left ventricle leads to reduced cardiac output with consequent systemic arterial and venous vasoconstriction. CHF develops generally in the course of months or years, and can be the end stage of chronic hypertension, infarction, angina, or diabetes. Heart failure, however caused, represents an intrinsic property of the muscle, and slow relaxation due to slow intracellular calcium removal by the sarcoplasmic reticulum is an important factor. In the normal, healthy heart the duration of contraction and relaxation decreases with increasing heart rate. This ensures a diastolic period of sufficient duration, which is important (a) for filling of the ventricle, and (b) because coronary perfusion and myocardial oxygen supply occurs only during diastole. The duration of contraction and relaxation is determined by calcium removal from the contractile filaments, mainly by the calcium pump in the sarcoplasmic reticulum Increased heart rate causes more rapid relaxation due to increased activation of the calcium pump. The latter mechanism is impaired in the hypertrophied or failing heart due to reduced transcription of the genes that supply the calcium pump proteins. Therefore, in heart failure patients an increase of heart rate may almost abolish the diastolic interval, which leads to reduced ventricular filling, and reduces myocardial blood supply (Davies et al., 1995, “Reduced Contraction and Altered Frequency Response of Isolated Ventricular Myocytes From Patients With Heart Failure,” Circulation 92: 2540-2549).
  • The syndrome of heart failure is a common course for the progression of many forms of heart disease. Heart failure may be considered to be the condition in which an abnormality of cardiac function is responsible for the inability of the heart to pump blood at a rate commensurate with the requirements of the metabolizing tissues, or can do so only at an abnormally elevated filling pressure. There are many specific disease processes that can lead to heart failure with a resulting difference in pathophysiology of the failing heart, such as the dilatation of the left ventricular chamber. Etiologies that can lead to this form of failure include idiopathic cardiomyopathy, viral cardiomyopathy, and ischemic cardiomyopathy. The process of ventricular dilatation is generally the result of chronic volume overload or specific damage to the myocardium In a normal heart that is exposed to long term increased cardiac output requirements, for example, that of an athlete, there is an adaptive process of ventricular dilation and myocyte hypertrophy. In this way, the heart fully compensates for the increased cardiac output requirements. With damage to the myocardium or chronic volume overload, however, there are increased requirements put on the contracting myocardium to such a level that this compensated state is never achieved and the heart continues to dilate. The basic problem with a large dilated left ventricle is that there is a significant increase in wall tension and/or stress both during diastolic filling and during systolic contraction. In a normal heart, the adaptation of muscle hypertrophy (thickening) and ventricular dilatation maintain a fairly constant wall tension for systolic contraction. However, in a failing heart, the ongoing dilatation is greater than the hypertrophy and the result is a rising wall tension requirement for systolic contraction. This is felt to be an ongoing insult to the muscle myocyte resulting in further muscle damage. The increase in wall stress is also true for diastolic filling. Additionally, because of the lack of cardiac output, there is generally a rise in ventricular filing pressure from several physiologic mechanisms. Moreover, in diastole there is both a diameter increase and a pressure increase over normal, both contributing to higher wall stress levels. The increase in diastolic wall stress is felt to be the primary contributor to ongoing dilatation of the chamber.
  • Presently available treatments for CHF fall into three generally categories: (1) pharmacological, e.g., diuretics; (2) assist systems, e.g., pumps; and (3) surgical treatments. With respect to pharmacological treatments, diuretics have been used to reduce the workload of the heart by reducing blood volume and preload. While drug treatment improves quality of life, it has little effect on survival. Current pharmacological treatment includes a combination of diuretics, vasodilators, inotropes, .beta.-blockers, and Angiotensin-Converting-Enzy- me (ACE)-inhibitors (Bristow & Gilbert, 1995, “Improvement in Cardiac Myocyte Function by Biological Effects of Medical Therapy: A New Concept in the Treatment of Heart Failure,” European Heart Journal 16, Supplement F: 20-31). The effect is a decrease of symptoms, and improved quality of life, but little change in mortality. Moreover, the exercise tolerance of most patients is extremely low, as a consequence of limited oxygen supply through the lungs. Long lasting lack of exercise and malnutrition may contribute to the condition and partly explain the exercise intolerance. Indeed, the lack of exercise and deterioration of cardiac muscle may each contribute to each other, with a snowballing effect (Coats et al., 1992, “Controlled Trial of Physical Training in Chronic Heart Failure: Exercise Perfolinance, Hemodynamics, Ventilation, and Autonomic Function,” Circulation 85: 2119-2131). Clinically, preload is defined in several ways including left ventricular end diastolic pressure (LVEDP), or left ventricular end diastolic volume (LVEDV). Physiologically, the preferred definition is the length of stretch of the sarcomere at end diastole. Diuretics reduce extra cellular fluid that builds in congestive heart failure patients increasing preload conditions. Nitrates, arteriolar vasodilators, angiotensin converting enzyme inhibitors have been used to treat heart failure through the reduction of cardiac workload through the reduction of afterload. Afterload may be defined as the tension or stress required in the wall of the ventricle during ejection. Inotropes such as digoxin are cardiac glycosides and function to increase cardiac output by increasing the force and speed of cardiac muscle contraction. These drug therapies offer some beneficial effects but do not stop the progression of the disease. Captopril, enalapril and other inhibitors of angiotensin-converting enzyme (ACE) have been used to treat congestive heart failure. See Merck Index, 1759 and 3521(11th ed. 1989); Kramer, B. L. et al. Circulation 1983, 67(4):755-763. However, such ACE inhibitors have generally provided only moderate or poor results. For example, captopril therapy generally provides only small increases in exercise time and functional capacity. Captopril also has provided only small reductions in mortality rates.
  • Assist devices used to treat CHF include, for example, mechanical pumps. Mechanical pumps reduce the load on the heart by performing all or part of the pumping function normally done by the heart. Currently, mechanical pumps are used to sustain the patient while a donor heart for transplantation becomes available for the patient. There are also a number of pacing devices used to treat CHF. However, in the chronic ischemic heart, high rate pacing may lead to increased diastolic pressure, indicating calcium overload and damage of the muscle fibers. Finally, there are at least three surgical procedures for treatment of heart failure: 1) heart transplant; 2) dynamic cardiomyoplasty; and 3) the Batista partial left ventriculectomy. Heart transplantation has serious limitations including restricted availability of organs and adverse effects of immunosuppressive therapies required following heart transplantation. Cardiomyoplasty includes wrapping the heart with skeletal muscle and electrically stimulating the muscle to contract synchronously with the heart in order to help the pumping function of the heart. The Batista partial left ventriculectomy includes surgically remodeling the left ventricle by removing a segment of the muscular wall. This procedure reduces the diameter of the dilated heart, which in turn reduces the loading of the heart. However, this extremely invasive procedure reduces muscle mass of the heart.
  • One category of CHF is diastolic heart failure (DHF), which afflicts between 30% and 70% of those patients with heart failure. DHF is an episodic clinical syndrome that can instigate pulmonary edema, possibly necessitating hospitalization and ventilatory support. The heart is a complex pump structured of two atria and two ventricles that pump blood in parallel into the pulmonary circulation at a relatively low pressure (right ventricle peak systolic pressure is about 25 mmHg) and the systemic circulation (left ventricle peak systolic pressure is about 120 mmHg). During the diastolic phase of the cardiac cycle the ventricles of the heart fill via the respective atria. The pressure differential that propels blood from the respective venous circulations to the atria and ventricles (systemic to the right ventricle and pulmonary to the left ventricle) is low, less than about 5 mmHg. On the left side, during diastole (when the mitral valve opens), pressure in the left atrium normally is not more than 12 mmHg. Due to active diastolic relaxation at the onset of diastole, the pressure difference between the left atrium and the left ventricle is augmented contributing to the early rapid diastolic filling of the left ventricle. Diastolic pressures in the atrium and the ventricle at this phase of the cardiac cycle drop quickly to less than 5 mmHg and equalize. At this point during diastole, the process of filling the left ventricle partially stops (diastiasis) and is renewed only towards late diastole, when active contraction of the atrium occurs, resulting in increased left atrial pressure and an increased pressure differential between the atrium and the ventricle. Atrial contraction is very important for maintaining adequate left ventricular filling during exercise and other states of increased cardiac output demand, or when the left ventricle fails to relax normally such as during ischemia or LV hypertrophy. Toward the end of diastole, pressure in the left ventricle (LVEDP) is increased but is normally not more than 12 mmHg.
  • Disease states in which active and passive relaxation properties of the left ventricle are disturbed, or the pumping and emptying capacity of the ventricle is reduced, may be translated to increased diastolic pressures in the left ventricle. The higher pressures and distension of the left ventricle cause a rise in wall stress and increased oxygen consumption. Up to a limit, the increased diastolic pressure and increased ventricular size result in augmented stroke volume. This compensatory mechanism is limited and has a significant physiologic price mainly when the slope of the pressure-volume curves turn steep, and left ventricular diastolic pressures becomes markedly high (>20 mmHg). At this point, a state of pulmonary congestion may ensue, turning later to a life threatening state of pulmonary edema.
  • A number of cardiovascular diseases can cause significant cardiac dysfunction and lead to the above-mentioned pathophysiologic state and pulmonary edema. These include: hypertension, ischemic heart disease state and post myocardial infarction, idiopathic dilated cardiomyopathy, valvular heart disease, including aortic stenosis, mitral stenosis, aortic regurgitation, mitral regurgitation, and combined valvular heart disease. Other primary myocardial diseases such as post partum and hypertrophic cardiomyopathy may cause similar conditions. In all these disease states with either decreased ability for the left ventricle to pump blood (systolic dysfunction) or reduced fling capacity (diastolic dysfunction) left ventricular diastolic pressure rises. Increased diastolic pressure in the left ventricle eventually in and of itself becomes a cause for greater degradation in cardiac function than occurred as a result of the original insult. The augmented pressures may cause as stated previously pulmonary congestion and dyspnea. At extreme conditions the clinical state may deteriorate to pulmonary edema.
  • There are several known techniques to attempt to overcome the state of left ventricular dysfunction, increased diastolic left ventricular pressures and pulmonary congestion. However, none are fully satisfactory. For example, pharmacological treatments are the only practical methods for chronic therapy for most of the population with congestive heart failure. The pharmacological agents used to treat congestive heart failure result in a reduction in diastolic pressure and prevention of pulmonary and peripheral congestion discussed above, i.e., diuretics, vasodilators and digoxin. Diuretics reduce the volume load and thereby reduce preload and diastolic wall stress. Vasodilators have a dual effect in reducing arterial resistance as well as increasing venous capacitance, thereby reducing preload and after load and wall stress throughout the cardiac cycle. These drugs, either direct acting on the vasculature or via neurohormonal mechanisms (ACE inhibitors), are limited in their effect since they may cause hypotension in a significant number of patients with myocardial dysfunction. These pharmacological agents are of limited value mainly because of their side effects. The use of diuretics is associated with side effects related to the drugs and to the detrimental effect on renal function. Vasodilators have also many side effects some of which limit the use of the drugs and their efficacy including hypotension in many patients. Drug therapy results in many of the patients in relative clinical stability. However, episodes where intraventricular diastolic pressure may rise above physiologic needs for cardiac stroke volume augmentation and culminate into pulmonary edema occur often and are very difficult to manage.
  • In extreme acute situations, temporary assist devices and intraaortic balloons may be helpful. Cardiac transplantation and chronic LVAD implants are solutions available for a small part of the patient population and as last resort. However, all the assist devices currently used are intended to improve pumping capacity of the heart and increase cardiac output to levels compatible with normal life. Finally, cardiac transplantation is another solution, but is not a very practical and is limited to extreme cases and as are the various assist devices. The mechanical devices were built to allow propulsion of significant amount of blood (liters/min) and this is also their main technological limitation. The need for power supply, relatively large pumps and danger of hemolysis and infection are all of significant concern.
  • Thus, there exists a long-felt and as of yet unsolved need for a treatment that addresses the course of congestive heart failure, and in particular the high pressure of the left ventricle and the compounding factors that are associated with it. It would therefore be desirable to provide methods, apparatus and treatments that beneficially reduce and regulate the pressure within the left ventricle. It is an object of the present invention to provide methods and apparatus for reducing left ventricular end diastolic pressure, and more particularly to provide methods and apparatus without deleterious side effects. It is a further object of the present invention to provide methods and apparatus that can be used in a minimally invasive manner for both acute and chronic treatments.
  • SUMMARY OF THE INVENTION
  • The present invention reduces the increased diastolic pressure that can occur as part of the clinical syndrome referred to as Congestive Heart Failure (CHF). Passive and semi-passive devices to reduce left ventricular end-diastolic pressure are disclosed, and in preferred embodiments, a shunt-type device allows a small volume of blood to be released from the left ventricle to reduce the pressure. Certain embodiments use a passive check-valve that allows flow only above a given threshold pressure, while others use a passive check-valve that allows flow only within a window between a lower pressure threshold and a higher-pressure threshold. Embodiments employing check valves prevent shunting during left ventricular systole. Alternatively, semi-passive embodiments have a valve activated by an external signal, such as an intra-corporeal electrical battery or an externally coupled energy source. A third type of preferred embodiment of the invention employs an device such as a pump to actively move blood, with the intent of preventing further deterioration of the patient's heart failure or allowing for some reversal of the heart failure. For example in patients presenting with diastolic heart failure (DHF) the present invention prevents this occurrence by reducing diastolic pressures in the left atrium below the excessive levels that would otherwise have caused pulmonary edema.
  • The present invention is thus directed to methods and apparatus for decreasing pressure in a first portion of a vessel of the cardiac structure of a patient by implanting a shunt communicating with an area outside said first portion, whereby a volume of blood sufficient to reduce pressure in said first portion is released. Preferably, the first portion comprises the left ventricle and the pressure reduced is the end diastolic pressure, which is accomplished by having the shunt communicate with the left ventricle so a small volume of blood is released from the left ventricle to reduce the end diastolic pressure. Most preferably, the shunt selectively permits flow when a pressure differential between the left ventricle and another chamber of a heart above a threshold pressure, whereby shunting is prevented during left ventricular systole, or, alternatively, selectively permits flow when a pressure differential between the left ventricle and another chamber of a heart is between a lower threshold and a higher threshold, whereby shunting is again prevented during left ventricular systole. In certain embodiments a semi-passive check-valve is controlled and actuated by an external signal, either using a signal generated by an intra-corporeal electrical battery or an externally coupled energy source. In certain embodiments, the shunt has a pump with an input connected to the left ventricle, or other portion with excessive pressure, and an output connected to a volume of lower pressure. The preferred method of implanting the shunt to effect the present invention is by deploying a tubular element having two ends and a tissue affixation element disposed at each of said ends via a catheter, preferably, the fixation element is a shape retaining metallic material that returns to its original shape as part of the retention aspect of its function. In preferred embodiments of the apparatus, the tubular element is comprised of a biologically inert non-metallic material.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a perspective view of a first embodiment of an implantable shunt made in accordance with the present invention;
  • FIG. 2 is a side elevation view, in cross-section as shown by lines 2-2 in FIG. 1, illustrating the placement of the shunt shown in FIG. 1 in a septum, and showing diagrammatically the use of a pump to augment flow in certain embodiments; and
  • FIGS. 3-5 are a cross sectional view of a patient receiving a shunt made in accordance with the present invention via percutaneous placement.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • Referring now to FIG. 1, there is shown a perspective view of a first embodiment of a shunt 100 made in accordance with the present invention. The shunt 100 is comprised of a fixation element 110, which is shown as a planar circular element. It will be understood, however, that the fixation element 110 can be circular, polygonal, spiral or many other shapes. Moreover, the fixation element can lie in a single plane or be curved in multiple planes, such as in a helical configuration. It can be constructed of a variety of materials that offer the elastic range and spring-like characteristics that will enable passage through a catheter lumen, or through the lumen of another implantation assistance device, in a relatively straightened configuration and then recovery of its fill fixation configuration shape. In certain embodiments, the fixation element can be made of reduced size and then expanded through the use of shape-memory alloys (SMA's), such as nickel-titanium (NiTi, also known as nitinol), that change shape in response to temperature changes and which are fabricated such that the temperature change from below body temperature to body temperature causes the shape conversion necessary for implantation. If SMA materials are not used, suitable materials include super-elastic metals, such as NiTi or stainless steel, such as the alloy ELGILOY®, commonly used for medical implants. Additionally, polymeric materials can be used to form the fixation element or as a coating over a metallic core. The fixation element may be coated and/or textured as so as to increase its biocompatability or to increase the degree to which it quickly becomes endothelialized, which may be desired in some implantation conditions.
  • As illustrated, the fixation element 110 surrounds and positions the shunt tube element 120, which is provided so as to enable passage of blood from a region of high pressure, such as the left atrium, to a region of lower pressure, such as the right atrium. The dimensions of the shunt tube element 120 are chosen so as to be as small as possible while still allowing sufficiently rapid fluid flow without endangering blood coagulation induced by blood stasis or low-flow zones. Computational fluid dynamics methods can be used to appropriately shape the element so as to minimize low-flow zones and maximize laminar flow. The inside diameter of the shunt tube is preferably greater than 1 mm and less than 5 mm, but it will be understood that a wide range of shapes and diameters can be constructed that will effect the purpose of the present invention in a variety of patients and flow conditions within those patients. The shunt tube element 120 is preferably formed of either metallic or polymeric materials and may be coated and/or textured as mentioned above. Pyrolitic carbon coating, as is commonly used in implantable mechanical heart valves, can be used to increase the degree to which the surface is biologically inert. Examples of such commercially available materials include On-X{circle over (R)} Carbon, from Medical Carbon Research Institute, LLC, of Austin, Tex.
  • Also illustrated in FIG. 1 is a valve element 130, which as explained below is not necessarily included in all embodiments within the scope of the present invention and can be of a variety of forms. As illustrated a leaflet 131,132 can be used, either in a single piece or as a dual leaflet design as illustrated. In the embodiment shown in FIG. 1, each leaflet 131,132 is a flat plate that pivots to open and close the orifice of the shunt tube. A ball-and-socket design can be used as well. Another alternative design is the duckbill-type valve. The valve element can be formed using the same range or materials and coatings mentioned above for the shunt tube.
  • From the foregoing, it will be appreciated by those of skill in the art that the present invention is well adapted to percutaneous placement via femoral access, however, other implantation techniques such as surgical techniques using either an open chest procedure or those using minimally invasive techniques are also within the scope of the present invention.
  • The concepts of allowing pressure to be relieved in one area of the circulation by shunting to an area of lower pressure as disclosed herein may take many embodiments, all of which will be apparent to those of skill in the art upon review of the foregoing descriptions of the physiology and medicine involved, and the description of the embodiment of FIG. 1.
  • In accordance with the present invention, the device may or may not include the valve element 130, since in certain patients or to treat certain conditions a valve would add complexity while not providing necessary functionality. Similarly, depending upon the circumstances of use, the valve element 130 may be either passive (actuated by the force of blood) or active (actuated by some other portion of the device). In active valve embodiments, the valve element 130 may include electric or electromagnetic elements that can be selectively actuated to open and close the valve element 130 or, if the valve element is designed for gradual opening and closing, move the valve element 130 between a first position and a second position. In some embodiments, the valve will be chosen and designed so that it responds only upon certain conditions occurring within the heart, such as the following: absolute left atrial pressure, differential atrial pressure, other intra-cardiac pressures, other cardiovascular pressures, or other physiological conditions that might correlate to an exacerbated state of diastolic heart failure, such as blood oxygen saturation or pH. In such embodiments, response to any given pressure or differential pressure will imply that a portion of the implanted device is in fluid communication with the relevant pressure source or sources. These embodiments will provide robust and reliable functionality by being mechanical and operating with signal inputs. All shunts, whether they include a valve or not can be further enhanced by including a check-valve that will prevent backflow. Those of skill in the art will appreciate that it is typically desirable to prevent flow from the right heart to the left heart, and thus one or more check valves can be appropriately placed. A double-check valve allows blood pressure above a lower limit but below a higher limit to actuate the valve, thus in a preferred embodiment, shunting blood from the left side to the right side only during a period of diastole.
  • Referring now to FIG. 2, another aspect of the devices of the present invention is that the shunt 100 may or may not be in fluid communication with a pump 140, such as either a surgically implanted pump that continuously moves a small amount of blood from one chamber or area to another, for example from the left ventricle chamber to the aorta for chronic reduction of LVEDP. Alternatively, the invention can include a catheter-based pump that continuously moves a small amount of blood from the LV chamber to the aorta for acute reduction of LVEDP. In certain preferred embodiments, the pump and valve will have a heart-synchronized actuated valve to allow specific regimens of left-to-right shunting to be applied. As seen in FIG. 2, after the shunt 100 is placed in a septum or other area, the pump 140 may be placed so as to direct fluid toward the shunt, the pump may be directly connected to the shunt, juxtaposed to the shunt, or displaced from the shunt but capable of directing flow in such a way as to effect more efficient pressure reduction.
  • FIG. 2 shows an implant similar to that of FIG. 1 that is placed surgically for the chronic reduction of LVEDP. This device includes a relatively small-sized pump 140, which can be similar to those used in Left-Ventricular Assist Devices (LVADs). Unlike the LVAD, however, the disclosed invention does not seek to significantly “support” the function of the left ventricle by pumping blood from the LV chamber to the body. Rather, it is intended only to “offload” the excessive pressure that builds through the diastolic phase of the cardiac cycle in some CBF patients. Whereas a normal LVEDP is in the range of 6 -12 mmHg, patients with diastolic dysfunction heart failure (DDHF), end-diastolic pressure (EDP) in the left atrium (LA) and left ventricle (LV) can rise considerably above normal levels. Therefore the present invention encompasses a number of embodiments that are both capable of being either implanted during a surgical procedure or using a catheter (percutaneous). The shunt 100 allows blood to flow in the direction shown by the arrows so long as there is a lower pressure in the chamber or vessel adjoining the LV. In any embodiment, the methods and apparatus of the present invention reduce EDP, and in particular mitigate the most severe consequences of significantly increased EDP, such as pulmonary edema.
  • Thus, in preferred embodiments of the present invention the shunt is disposed in a wall between the chambers of a patient's heart, and most preferably, disposed in the atrial septum to permit blood to flow from the left ventricle when the pressure within the ventricle exceeds the pressure of the adjoining atrial chamber. In another particular embodiment, a sophisticated shunt apparatus implanted in the intra-atrial septum to allow intermittent and controlled blood flow from the left atrium to the right atrium (RA), thereby reducing LAEDP. Alternatively, the shunt might have its origin in locations other than the LA, such as the LV, and might have its output at locations other than the RA, such as the light ventricle (RV).
  • As explained above, although one class of embodiments of the present invention is designed to be purely mechanical and will have certain advantages, the present invention also encompasses additional embodiments wherein additional features such as internal signal processing unit 148 and an energy source 150, such as a battery, are included. In such embodiments, the shunts described above will include a valve apparatus that responds to conditions other than those occurring within the heart and/or has internal signal processing requiring an energy source. A device of this type responds according to programmed algorithms to all of the conditions mentioned above. The signal processing ability of devices in such embodiments enable adaptive approaches as well, in which the device response to conditions will change over time according to a pre-programmed adaptation algorithm. Such embodiments will include additional apparatus, such as a power source 150, sensors 155 and the like. The provision of implantable, programmable electrical devices that collect cardiac data and effect the operation of certain other elements of a device are well known in the field of cardiac pacing, for one example. In one particular embodiment, the actively controlled valve of the shunt as in senses and responds to electrical signals so as to act in synchronization with the cardiac cycle.
  • Either passive or active devices may be linked to an external indicator 157, such as pendant worn by the patient, that displays the device status. Such an indicator enables the patient to notify a physician in the event of an activation of the implanted device that corresponds to the significantly exacerbated state heart failure. In this case, the device will be acting to prevent the occurrence of pulmonary edema during the time that the patient notifies a physician and then undergoes medical treatment to reduce the severity of the patient's condition.
  • Similarly, any embodiment of the present invention may be designed so that an external device can be used on occasion to either mechanically adjust (in the case of passive devices; for example, by magnetic coupling) and/or to reprogram (in the case of active devices) the functioning of the implanted device.
  • The methods mentioned above will prevent from excessive pressures to build up in the left ventricle and help restore wall stress in diastole and systole to normal values quickly thus helping the introduction of pharmacological agents as adjunct therapy or vice versa. This mode of therapy will be complementary to the current management of the patients and allow more controlled stabilization. It can be added as a component of cardiac pacemaker (dual or biventricular) and derive the power supply from the pacemaker battery.
  • The pressure/flow/volume requirements of the various embodiments of the present invention will be determined using methodologies similar to those used to design a Left Ventricular Assist Device (LVAD) but with certain distinctly different flow requirements, rather than the intent of supporting systemic circulation requirements found in a LVAD. Thus, certain shunts made in accordance with the present invention can use designs and dimensions that would not be appropriate or adequate for an LVAD. Patients with heart failure dominated by systolic dysfunction exhibit contraction abnormalities, whereas those in diastolic dysfunction exhibit relaxation abnormalities. In most patients there is a mixed pathophysiology. Normal pulmonary venous pressure (PVP) necessary for the normal LV to adequately fill and pump is less than 12 mmHg. Patients with systolic dysfunction have larger LV volume to maintain SV and may need increased PVP to fill (mixed systolic diastolic dysfunction). Patients with diastolic dysfunction need increased PVP for the LV to fill and adequately pump.
  • The hemodynamic performance of the present invention, and thus the design of the shunt and its actuation, placement etc. will be determined by a variety of factors, for example, the following table is in the form of:
  • IF ({LAEDP} AND/OR {Mean LA P}) AND/OR ({ΔLAEDP-RAEDP} AND/OR {ΔMean LA P-Mean RA P}) THEN {ACTION}
  • In which LAEDP, Mean LA P, RAEDP and Mean RA P refer to minima, maxima or ranges for the respective pressures (please specify which in the table), and the AND/OR indicate that a logical operator or an NA (not applicable) should be entered
  • Mean Δ Δ mean
    Sce- IF AND/ LA AND/ Atrial AND/ atrial Then
    nario LAEDP OR P OR EDP OR P (Action)
    Ex. Ex- Or Ex- NA NA NA NA Remove
    ceeds ceeds sufficient
    25 20 blood from
    the LA to
    reduce LA
    pressure
    by 5
    mmHg
  • Thus for example, a chronic device can be a preventive device where when pressures rise for some reason to dangerous levels the pump goes into action and helps to lower the pressure in the left ventricle, thereby preventing the acute development of dyspnea and pulmonary edema and assures that the LVDP are always at an optimal level of no more than 15 mmHg.
  • In other embodiments and for other indications, the present invention might move an extra volume of blood from the LV into the aorta. To do so, the pump 140 must be capable of moving blood from a chamber exhibiting 20 mmHg in diastole to 70 mmHg in the aorta. Another possible chamber where blood from the LA (throughout the cardiac cycle) or LV (only in diastole) can be directed to is the Right Atrium, and alternatively right ventricle. The benefit of directing blood from LA to RA is that the pressure differences are smaller and the blood can be moved in diastole and systole as well. Filling of the atria (R and L) during the systolic phase of the cardiac cycle determines the pressure in the atria at the onset of diastole and the opening of the valves.
  • Those of skill in the art will appreciate that there are a number of techniques for placement and locations for placement of shunts made in accordance with the present invention. For example, a surgically implanted passive shunt can be placed between the left ventricle and the right atrium for chronic reduction of LVEDP. Alternatively, a surgically implanted passive shunt can be placed between the left atrium and the right atrium for chronic reduction of LVEDP. For percutaneous placement, a catheter-based passive shunt can be inserted from the right atrium trans-septally into the left atrium for acute reduction of LVEDP. Another catheter-delivered embodiment is a passive shunt that is implanted from the right atrium trans-septally into the left atrium for chronic reduction of LVEDP.
  • Although the present invention provides new and useful methods of treatment, the techniques of implanting shunts as described herein is well known. For one example, in a preferred embodiment of the present invention, as illustrated in FIGS. 3-5, a transseptal needle set 160 is advanced toward the wall of the right atrial septum. Access has been made from the femoral vein with the system being advanced through the inferior vena cava and into the right atrium. Devices that allow such access and subsequent transseptal puncture are available from Cook Incorporated. For example, the procedure can be carried out using a stainless steel and obrturator set TSNC-18-71.0 for adults and TSNC-19-56.0 for pediatric patients. Once transseptal puncture has been achieved, a guidewire 170 is exchanged for the needle component in the commercially available device described above and then passed into the left atrium. The process of securing catheter access to the left atrium by way of a transseptal puncture is further described in the standard medical text Braunwald, Heart Disease, (Ch. 6, p. 186 ) which is incorporated herein by reference. After the transseptal sheath 165 is positioned in the left atrium, as described above, the placement of a shunt 100 made in accordance with the present invention is initiated. The following is a generalized sequence; the placement procedure will be done according to the typical methods of interventional cardiology as are well known to physicians trained in that subspecialty. The typical supporting apparatus found in the cardiac catheterization laboratory will be used, such as fluoroscopy for visualization and hemodynamic and ECG monitoring equipment to assess catheter position and patient vital signs.
  • The dilator and wire will be withdrawn from the sheath that now extends from the femoral vein access point in the patients groin to the left atrium, traversing the femoral vein, the illiac vein, the inferior vena cava, the right atrium, and the atrial septum The delivery catheter will be passed through the sheath while under fluoroscopic visualization. Radiopaque markers are provided on this catheter as well as the sheath in order to locate specific points. The delivery catheter is carefully and slowly advanced so that the most distal portion of the left-atrial fixation wire is emitted from the distal opening of the catheter and into the chamber of the left atrium. The fixation wire is formed from a spring-like material and/or may be super-elastic of shape-memory alloy, so that as it leaves the constraint provided by the inner lumen of the delivery catheter, it reforms into its fully formed shape, which may circular or polygonal as previously disclosed. The assembly of the sheath and the delivery catheter are then slowly retracted en bloc so as to withdraw the fixation wire towards the atrial septum. The physician stops this retraction when it becomes apparent by fluoroscopic visualization as well as by tactile feedback that the fixation wire has become seated against the atrial septum. At that point, the sheath alone is retracted, uncovering the shunt and positioning it within the opening that has been created within the atrial septum. The sheath is then further retracted, allowing the right-atrial fixation wire to reform into its fully formed shape. The entire shunt assembly is then detached from the delivery catheter system The shunt is controlled within the delivery catheter by means of long controller wire that has independent translational control within the catheter lumen. This attachment is formed by any conventional method, e.g., a solder or adhesive or the like that will mechanically detach at a prescribed tension level, that level being exceeded by the physician at this point in the procedure by firmly retracting the controller wire.
  • Although certain embodiments have been set forth and described herein, numerous alterations, modifications, and adaptations of the concepts presented will be immediately apparent to those of skill in the art, and accordingly will lie within the scope of the present invention, as defined by the claims appended hereto.

Claims (35)

  1. 1. A method of decreasing blood pressure in a heart, comprising:
    implanting a shunt with a valve element between a left atrium and a right atrium of the heart.
  2. 2. The method of claim 1 wherein said implanting includes deploying a tubular element having two ends and two fixation elements disposed at said two ends respectively.
  3. 3. The method of claim 1, comprising allowing an amount of blood suitable to substantially reduce blood pressure in the left atrium to flow from said left atrium to said said right atrium via said shunt when the pressure differential between said left atrium and said right atrium reaches a threshold.
  4. 4. The method of claim 1, comprising puncturing a transseptal hole and wherein implanting the shunt comprises implanting in the punctured transseptal hole.
  5. 5. A shunt for decreasing blood pressure in a heart, comprising:
    a valve suitable for operation between chambers of a heart, adapted to open only when a pressure level between opposite ends of the valve is above a threshold pressure greater than a normal pressure level over the cardiac cycle between the left atria and the right atria of a normal heart.
  6. 6. A shunt according to claim 5, wherein the valve is adapted to allow passage of blood therethrough throughout the cardiac cycle.
  7. 7. A shunt according to claim 5, wherein the valve is adapted to be implanted in an internal wall of the heart,
  8. 8. A shunt according to claim 5, wherein the valve is purely mechanical.
  9. 9. A shunt according to claim 5, wherein the valve is adapted to open under predetermined conditions which do not change without human intervention.
  10. 10. A shunt according to claim 5, wherein the threshold has a value such that when a pressure difference between the left and right atriums is greater than the threshold, the patient is considered suffering from pulmonary edema.
  11. 11. A shunt according to claim 5, wherein the threshold has a value such that when a pressure difference between the left and right atriums is greater than the threshold, the patient is considered in an exacerbated state of heart failure.
  12. 12. A shunt according to claim 5, wherein the valve is configured to open only when a pressure between the opposite ends of the valve is between a lower pressure threshold and a higher pressure threshold.
  13. 13. A shunt according to claim 5, comprising a tube encompassing the valve.
  14. 14. A shunt according to claim 13, wherein the tube has a diameter of less than 5 mm.
  15. 15. A shunt according to claim 13, wherein the valve is configured to allow passage of a relatively small volume of blood relative to an ejection volume of the heart.
  16. 16. A shunt according to claim 13, wherein the tube has a length not substantially greater than a thickness of walls between chambers of the heart.
  17. 17. A shunt according to claim 5, wherein the valve allows continuous flow of a small amount of blood.
  18. 18. A shunt according to claim 5, wherein the valve is adapted to open gradually.
  19. 19. A shunt according to claim 5, wherein the valve is configured to close after the pressure level between opposite ends of the valve reduces by a predetermined value.
  20. 20. A shunt according to claim 5, comprising at least one fixation element connected to the valve and adapted to be fixed to the heart.
  21. 21. A shunt according to claim 20, wherein the at least one fixation element comprises at least two fixation elements.
  22. 22. A shunt according to claim 21, wherein the valve is located in a tube and wherein a first one of the fixation elements is located on a first end of the tube and a second one of the fixation elements is located on a second end of the tube.
  23. 23. A shunt according to claim 5, wherein the valve comprises a tubular element including at least a flat pivoting plate.
  24. 24. A method of controlled decreasing of blood pressure in a heart chamber, comprising:
    providing a valve adapted to operate within a heart; and
    implanting the valve in a heart between two heart chambers, such that the valve opens responsive to a pressure level of an exacerbated state of heart failure but not under normal pressures of systole and diastole of a normal heart.
  25. 25. The method of claim 24, wherein implanting the valve in the heart comprises implanting between a first atrium and a second atrium.
  26. 26. The method of claim 24, wherein implanting the valve in the heart comprises implanting between a left atrium and a right atrium, such that opening the valve allows flow of blood from the left atrium to the right atrium.
  27. 27. The method of claim 24, wherein providing the valve comprises providing a valve configured to open only when the pressure in the left atrium is above a predetermined threshold.
  28. 28. The method of claim 27, wherein providing the valve comprises providing a valve configured to open only when the pressure in the left atrium is above 12 mmHg.
  29. 29. The method of claim 24, wherein implanting the valve comprises implanting in a septum.
  30. 30. The method of claim 24, wherein the valve is adapted to allow passage of blood therethrough only during diastole.
  31. 31. The method of claim 24, wherein the valve is configured to open when the heart suffers from an exacerbated absolute arterial pressure or an exacerbated differential arterial pressure.
  32. 32. The method of claim 24, wherein the valve is configured to close after drainage of an amount of blood sufficient to reduce the mean left atrium pressure by 5 mmHg.
  33. 33. The method of claim 24, wherein the valve is configured to open responsive to a differential pressure level between its opposite ends.
  34. 34. The method of claim 24, wherein implanting the valve comprises implanting in a percutaneous procedure.
  35. 35. The method of claim 24, comprising puncturing a transseptal hole and wherein implanting the valve comprises implanting the valve in the transseptal hole.
US13107843 2001-04-20 2011-05-13 Methods and apparatus for reducing localized circulatory system pressure Active US8328751B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09839643 US8091556B2 (en) 2001-04-20 2001-04-20 Methods and apparatus for reducing localized circulatory system pressure
US13107843 US8328751B2 (en) 2001-04-20 2011-05-13 Methods and apparatus for reducing localized circulatory system pressure

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13107843 US8328751B2 (en) 2001-04-20 2011-05-13 Methods and apparatus for reducing localized circulatory system pressure
US13708794 US9943670B2 (en) 2001-04-20 2012-12-07 Methods and apparatus for reducing localized circulatory system pressure
US14154088 US20140128796A1 (en) 2001-04-20 2014-01-13 Methods and apparatus for reducing localized circulatory system pressure
US14154080 US20140128795A1 (en) 2001-04-20 2014-01-13 Methods and apparatus for reducing localized circulatory system pressure

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09839643 Continuation US8091556B2 (en) 2001-04-20 2001-04-20 Methods and apparatus for reducing localized circulatory system pressure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13708794 Division US9943670B2 (en) 2001-04-20 2012-12-07 Methods and apparatus for reducing localized circulatory system pressure

Publications (2)

Publication Number Publication Date
US20110218478A1 true true US20110218478A1 (en) 2011-09-08
US8328751B2 US8328751B2 (en) 2012-12-11

Family

ID=25280294

Family Applications (6)

Application Number Title Priority Date Filing Date
US09839643 Active US8091556B2 (en) 2001-04-20 2001-04-20 Methods and apparatus for reducing localized circulatory system pressure
US13107843 Active US8328751B2 (en) 2001-04-20 2011-05-13 Methods and apparatus for reducing localized circulatory system pressure
US13107832 Active US8235933B2 (en) 2001-04-20 2011-05-13 Methods and apparatus for reducing localized circulatory system pressure
US13708794 Active US9943670B2 (en) 2001-04-20 2012-12-07 Methods and apparatus for reducing localized circulatory system pressure
US14154080 Pending US20140128795A1 (en) 2001-04-20 2014-01-13 Methods and apparatus for reducing localized circulatory system pressure
US14154088 Abandoned US20140128796A1 (en) 2001-04-20 2014-01-13 Methods and apparatus for reducing localized circulatory system pressure

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09839643 Active US8091556B2 (en) 2001-04-20 2001-04-20 Methods and apparatus for reducing localized circulatory system pressure

Family Applications After (4)

Application Number Title Priority Date Filing Date
US13107832 Active US8235933B2 (en) 2001-04-20 2011-05-13 Methods and apparatus for reducing localized circulatory system pressure
US13708794 Active US9943670B2 (en) 2001-04-20 2012-12-07 Methods and apparatus for reducing localized circulatory system pressure
US14154080 Pending US20140128795A1 (en) 2001-04-20 2014-01-13 Methods and apparatus for reducing localized circulatory system pressure
US14154088 Abandoned US20140128796A1 (en) 2001-04-20 2014-01-13 Methods and apparatus for reducing localized circulatory system pressure

Country Status (1)

Country Link
US (6) US8091556B2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8460372B2 (en) 2006-11-07 2013-06-11 Dc Devices, Inc. Prosthesis for reducing intra-cardiac pressure having an embolic filter
US8740962B2 (en) 2006-11-07 2014-06-03 Dc Devices, Inc. Prosthesis for retrieval and deployment
US8882697B2 (en) 2006-11-07 2014-11-11 Dc Devices, Inc. Apparatus and methods to create and maintain an intra-atrial pressure relief opening
US8951223B2 (en) 2011-12-22 2015-02-10 Dc Devices, Inc. Methods and devices for intra-atrial shunts having adjustable sizes
US9005155B2 (en) 2012-02-03 2015-04-14 Dc Devices, Inc. Devices and methods for treating heart failure
US9232997B2 (en) 2006-11-07 2016-01-12 Corvia Medical, Inc. Devices and methods for retrievable intra-atrial implants
US9277995B2 (en) 2010-01-29 2016-03-08 Corvia Medical, Inc. Devices and methods for reducing venous pressure
US9358371B2 (en) 2006-11-07 2016-06-07 Corvia Medical, Inc. Intra-atrial implants made of non-braided material
US9649480B2 (en) 2012-07-06 2017-05-16 Corvia Medical, Inc. Devices and methods of treating or ameliorating diastolic heart failure through pulmonary valve intervention
US9775636B2 (en) 2013-03-12 2017-10-03 Corvia Medical, Inc. Devices, systems, and methods for treating heart failure

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8091556B2 (en) 2001-04-20 2012-01-10 V-Wave Ltd. Methods and apparatus for reducing localized circulatory system pressure
US20040162514A1 (en) * 2003-02-14 2004-08-19 Scout Medical Technologies System and method for controlling differential pressure in a cardio-vascular system
JP2004345363A (en) * 2003-03-18 2004-12-09 Calsonic Kansei Corp Air duct for vehicle
WO2004091696A1 (en) * 2003-04-08 2004-10-28 The Board Of Trustees Of The Leland Stanford Junior University Implantable arteriovenous shunt device
US20040215323A1 (en) * 2003-04-24 2004-10-28 Medtronic Ave, Inc. Membrane eyelet
US20040215067A1 (en) * 2003-04-24 2004-10-28 Stiger Mark L. Flow sensor device for endoscopic third ventriculostomy
US7530963B2 (en) 2003-04-24 2009-05-12 Wisconsin Alumni Research Foundation Method of maintaining patency of opening in third ventricle floor
US20050165344A1 (en) * 2003-11-26 2005-07-28 Dobak John D.Iii Method and apparatus for treating heart failure
EP1547526A1 (en) * 2003-12-23 2005-06-29 UMC Utrecht Holding B.V. Operation element, operation set and method for use thereof
EP1771132A4 (en) * 2004-02-03 2009-12-16 Atria Medical Inc Device and method for controlling in-vivo pressure
US20060067972A1 (en) * 2004-06-23 2006-03-30 Flowmedica, Inc. Devices for renal-based heart failure treatment
US9681948B2 (en) * 2006-01-23 2017-06-20 V-Wave Ltd. Heart anchor device
US20070203516A1 (en) * 2006-02-24 2007-08-30 Medtronic Vascular (A Delaware Corporation) Apparatus and Methods for Creating an Opening in a Tissue Membrane
DE602007002292D1 (en) * 2006-04-19 2009-10-15 Transpid Ltd Device for the controlled Blutregurgitation through the tricuspid valve
US9757107B2 (en) 2009-09-04 2017-09-12 Corvia Medical, Inc. Methods and devices for intra-atrial shunts having adjustable sizes
US20080208214A1 (en) * 2007-02-26 2008-08-28 Olympus Medical Systems Corp. Applicator and tissue fastening method through natural orifice
US8428698B2 (en) * 2009-03-04 2013-04-23 Pacesetter, Inc. Systems and methods for monitoring DP, IVRT, DiFT, diastolic function and/or HF
JP5002740B1 (en) * 2009-04-28 2012-08-15 ディーシー ディヴァイシーズ インコーポレイテッド Apparatus for treating heart failure, the system and method
EP2427143B1 (en) 2009-05-04 2017-08-02 V-Wave Ltd. Device for regulating pressure in a heart chamber
US10076403B1 (en) 2009-05-04 2018-09-18 V-Wave Ltd. Shunt for redistributing atrial blood volume
US9034034B2 (en) 2010-12-22 2015-05-19 V-Wave Ltd. Devices for reducing left atrial pressure, and methods of making and using same
US9629715B2 (en) 2011-07-28 2017-04-25 V-Wave Ltd. Devices for reducing left atrial pressure having biodegradable constriction, and methods of making and using same
US9597205B2 (en) 2012-06-06 2017-03-21 Magenta Medical Ltd. Prosthetic renal valve
US9445797B2 (en) 2012-09-13 2016-09-20 Medtronic, Inc. Percutaneous atrial and ventricular septal defect closure device
CA2905349A1 (en) 2013-03-13 2014-09-18 Magenta Medical Ltd. Renal pump
EP2999412A2 (en) 2013-05-21 2016-03-30 V-Wave Ltd. Apparatus for delivering devices for reducing left atrial pressure
US9764113B2 (en) 2013-12-11 2017-09-19 Magenta Medical Ltd Curved catheter
GB2527075A (en) 2014-03-17 2015-12-16 Daassist As Percutaneous system, devices and methods
EP3154450A4 (en) 2014-06-13 2018-01-10 Intershunt Technologies, Inc. Method and catheter for creating an interatrial aperture
EP3169251A4 (en) * 2014-07-20 2018-03-14 Elchanan Bruckheimer Pulmonary artery implant apparatus and methods of use thereof
US20160022970A1 (en) * 2014-07-23 2016-01-28 Stephen J. Forcucci Devices and methods for treating heart failure
WO2016097976A1 (en) * 2014-12-16 2016-06-23 Tamburino Corrado Pumping system, endoluminal device and system for creating a two-way blood flow
CN106063954A (en) * 2015-04-21 2016-11-02 焦雷 Medical instrument implantation blood pump
EP3090766B1 (en) * 2015-05-06 2017-08-16 Peter Osypka Stiftung Device for regulating the vital parameters of the cardiovascular system
US9789294B2 (en) 2015-10-07 2017-10-17 Edwards Lifesciences Corporation Expandable cardiac shunt
USD810941S1 (en) 2016-10-06 2018-02-20 Edwards Lifesciences Corporation Cardiac shunt

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3874388A (en) * 1973-02-12 1975-04-01 Ochsner Med Found Alton Shunt defect closure system
US3952334A (en) * 1974-11-29 1976-04-27 General Atomic Company Biocompatible carbon prosthetic devices
FR2550583B1 (en) * 1983-08-08 1986-03-28 Delecroix Michel A regulation of a pump
US4705507A (en) * 1984-05-02 1987-11-10 Boyles Paul W Arterial catheter means
US4601309A (en) * 1985-04-23 1986-07-22 The United States Of America As Represented By The United States Department Of Energy Valve and dash-pot assembly
US4836204A (en) * 1987-07-06 1989-06-06 Landymore Roderick W Method for effecting closure of a perforation in the septum of the heart
US4979955A (en) * 1988-06-06 1990-12-25 Smith Robert M Power assisted prosthetic heart valve
US4995857A (en) * 1989-04-07 1991-02-26 Arnold John R Left ventricular assist device and method for temporary and permanent procedures
US5186431A (en) * 1989-09-22 1993-02-16 Yehuda Tamari Pressure sensitive valves for extracorporeal circuits
US5267940A (en) * 1989-11-29 1993-12-07 The Administrators Of The Tulane Educational Fund Cardiovascular flow enhancer and method of operation
CA2441679A1 (en) * 1991-05-16 1992-11-26 3F Therapeutics, Inc. Cardiac valve
US5584803A (en) * 1991-07-16 1996-12-17 Heartport, Inc. System for cardiac procedures
JP3393383B2 (en) * 1992-01-21 2003-04-07 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Septal defect closure device
EP0888758B1 (en) 1992-05-08 2003-08-20 Schneider (Usa) Inc., Esophageal stent
US5332402A (en) * 1992-05-12 1994-07-26 Teitelbaum George P Percutaneously-inserted cardiac valve
US5290227A (en) * 1992-08-06 1994-03-01 Pasque Michael K Method of implanting blood pump in ascending aorta or main pulmonary artery
US5312341A (en) * 1992-08-14 1994-05-17 Wayne State University Retaining apparatus and procedure for transseptal catheterization
US5429144A (en) * 1992-10-30 1995-07-04 Wilk; Peter J. Coronary artery by-pass method
US5409019A (en) * 1992-10-30 1995-04-25 Wilk; Peter J. Coronary artery by-pass method
US5326374A (en) * 1992-12-01 1994-07-05 Michael N. Ilbawi Body-implantable device for controlling the size of a fluid passageway
US5713950A (en) * 1993-11-01 1998-02-03 Cox; James L. Method of replacing heart valves using flexible tubes
US5531759A (en) 1994-04-29 1996-07-02 Kensey Nash Corporation System for closing a percutaneous puncture formed by a trocar to prevent tissue at the puncture from herniating
US5597377A (en) * 1994-05-06 1997-01-28 Trustees Of Boston University Coronary sinus reperfusion catheter
US5725552A (en) * 1994-07-08 1998-03-10 Aga Medical Corporation Percutaneous catheter directed intravascular occlusion devices
US5904697A (en) 1995-02-24 1999-05-18 Heartport, Inc. Devices and methods for performing a vascular anastomosis
CA2215498A1 (en) * 1995-03-29 1996-10-03 Cv Dynamics, Inc. Bileaflet heart valve
EP0819014B1 (en) * 1995-03-30 2003-02-05 Heartport, Inc. Endovascular cardiac venting catheter
US5556386A (en) * 1995-04-03 1996-09-17 Research Medical, Inc. Medical pressure relief valve
US5662711A (en) * 1995-06-07 1997-09-02 Douglas; William Flow adjustable artery shunt
US5702412A (en) 1995-10-03 1997-12-30 Cedars-Sinai Medical Center Method and devices for performing vascular anastomosis
US6039759A (en) * 1996-02-20 2000-03-21 Baxter International Inc. Mechanical prosthetic valve with coupled leaflets
US5810836A (en) 1996-03-04 1998-09-22 Myocardial Stents, Inc. Device and method for trans myocardial revascularization (TMR)
US5853422A (en) * 1996-03-22 1998-12-29 Scimed Life Systems, Inc. Apparatus and method for closing a septal defect
US6447539B1 (en) * 1996-09-16 2002-09-10 Transvascular, Inc. Method and apparatus for treating ischemic heart disease by providing transvenous myocardial perfusion
US5655548A (en) * 1996-09-16 1997-08-12 Circulation, Inc. Method for treatment of ischemic heart disease by providing transvenous myocardial perfusion
US6165188A (en) * 1996-12-02 2000-12-26 Angiotrax, Inc. Apparatus for percutaneously performing myocardial revascularization having controlled cutting depth and methods of use
DK1671604T3 (en) * 1996-12-10 2009-11-09 Purdue Research Foundation Synthetic tissue valve of
US5795307A (en) * 1997-04-29 1998-08-18 Krueger; John A. Shunt tap apparatus and method
US5957949A (en) * 1997-05-01 1999-09-28 World Medical Manufacturing Corp. Percutaneous placement valve stent
EP0923792B1 (en) 1997-05-16 2007-02-07 Philips Electronics N.V. Silicon germanium semiconductor device and a method of manufacturing the same
US6120534A (en) 1997-10-29 2000-09-19 Ruiz; Carlos E. Endoluminal prosthesis having adjustable constriction
US6589198B1 (en) * 1998-01-29 2003-07-08 David Soltanpour Implantable micro-pump assembly
US6638303B1 (en) * 1998-03-13 2003-10-28 Carbomedics, Inc. Heart valve prosthesis
US7083588B1 (en) 1998-05-26 2006-08-01 Medtronic Vascular, Inc. Apparatus for providing coronary retroperfusion and methods of use
GB9816173D0 (en) * 1998-07-25 1998-09-23 Huntleigh Technology Plc Pneumatic systems
US6260552B1 (en) 1998-07-29 2001-07-17 Myocor, Inc. Transventricular implant tools and devices
US6406488B1 (en) * 1998-08-27 2002-06-18 Heartstent Corporation Healing transmyocardial implant
EP1669042A3 (en) * 1998-09-10 2006-06-28 Percardia, Inc. TMR shunt
US6641610B2 (en) * 1998-09-10 2003-11-04 Percardia, Inc. Valve designs for left ventricular conduits
US6254564B1 (en) * 1998-09-10 2001-07-03 Percardia, Inc. Left ventricular conduit with blood vessel graft
US6245099B1 (en) 1998-09-30 2001-06-12 Impra, Inc. Selective adherence of stent-graft coverings, mandrel and method of making stent-graft device
DE19855422A1 (en) * 1998-12-01 2000-06-08 Basf Ag Hard sintered molding having a nickel- and cobalt-free, nitrogen-containing steel as a binder of the hard phase
US6217541B1 (en) * 1999-01-19 2001-04-17 Kriton Medical, Inc. Blood pump using cross-flow principles
US6210318B1 (en) * 1999-03-09 2001-04-03 Abiomed, Inc. Stented balloon pump system and method for using same
US6695859B1 (en) 1999-04-05 2004-02-24 Coalescent Surgical, Inc. Apparatus and methods for anastomosis
CA2620783C (en) * 1999-04-09 2011-04-05 Evalve, Inc. Methods and apparatus for cardiac valve repair
US6287335B1 (en) 1999-04-26 2001-09-11 William J. Drasler Intravascular folded tubular endoprosthesis
US6712836B1 (en) 1999-05-13 2004-03-30 St. Jude Medical Atg, Inc. Apparatus and methods for closing septal defects and occluding blood flow
US6790229B1 (en) 1999-05-25 2004-09-14 Eric Berreklouw Fixing device, in particular for fixing to vascular wall tissue
US6344022B1 (en) * 1999-07-19 2002-02-05 Robert Jarvik Right ventricular bypass devices and methods of their use during heart surgery
US7892246B2 (en) * 1999-07-28 2011-02-22 Bioconnect Systems, Inc. Devices and methods for interconnecting conduits and closing openings in tissue
US6302892B1 (en) * 1999-08-04 2001-10-16 Percardia, Inc. Blood flow conduit delivery system and method of use
US20070043435A1 (en) 1999-11-17 2007-02-22 Jacques Seguin Non-cylindrical prosthetic valve system for transluminal delivery
US8579966B2 (en) 1999-11-17 2013-11-12 Medtronic Corevalve Llc Prosthetic valve for transluminal delivery
US8016877B2 (en) 1999-11-17 2011-09-13 Medtronic Corevalve Llc Prosthetic valve for transluminal delivery
US6277078B1 (en) * 1999-11-19 2001-08-21 Remon Medical Technologies, Ltd. System and method for monitoring a parameter associated with the performance of a heart
US6458153B1 (en) * 1999-12-31 2002-10-01 Abps Venture One, Ltd. Endoluminal cardiac and venous valve prostheses and methods of manufacture and delivery thereof
US6328699B1 (en) * 2000-01-11 2001-12-11 Cedars-Sinai Medical Center Permanently implantable system and method for detecting, diagnosing and treating congestive heart failure
ES2307590T3 (en) 2000-01-27 2008-12-01 3F Therapeutics, Inc Prosthetic heart valve.
US6475136B1 (en) 2000-02-14 2002-11-05 Obtech Medical Ag Hydraulic heartburn and reflux treatment
US6406422B1 (en) 2000-03-02 2002-06-18 Levram Medical Devices, Ltd. Ventricular-assist method and apparatus
US6468303B1 (en) * 2000-03-27 2002-10-22 Aga Medical Corporation Retrievable self expanding shunt
US6478776B1 (en) 2000-04-05 2002-11-12 Biocardia, Inc. Implant delivery catheter system and methods for its use
US7056294B2 (en) 2000-04-13 2006-06-06 Ev3 Sunnyvale, Inc Method and apparatus for accessing the left atrial appendage
US6527698B1 (en) * 2000-05-30 2003-03-04 Abiomed, Inc. Active left-right flow control in a two chamber cardiac prosthesis
US6358277B1 (en) * 2000-06-21 2002-03-19 The International Heart Institute Of Montana Foundation Atrio-ventricular valvular device
US6572652B2 (en) * 2000-08-29 2003-06-03 Venpro Corporation Method and devices for decreasing elevated pulmonary venous pressure
US20040093075A1 (en) * 2000-12-15 2004-05-13 Titus Kuehne Stent with valve and method of use thereof
US6544208B2 (en) * 2000-12-29 2003-04-08 C. Ross Ethier Implantable shunt device
US6562066B1 (en) * 2001-03-02 2003-05-13 Eric C. Martin Stent for arterialization of the coronary sinus and retrograde perfusion of the myocardium
US6632169B2 (en) * 2001-03-13 2003-10-14 Ltk Enterprises, L.L.C. Optimized pulsatile-flow ventricular-assist device and total artificial heart
US8091556B2 (en) 2001-04-20 2012-01-10 V-Wave Ltd. Methods and apparatus for reducing localized circulatory system pressure
GB2378760A (en) 2001-04-20 2003-02-19 Marconi Medical Systems Uk Ltd Surgical Probe
CA2446920A1 (en) * 2001-05-21 2002-11-28 Medtronic, Inc. Trans-septal catheter with retention mechanism
US6685664B2 (en) 2001-06-08 2004-02-03 Chf Solutions, Inc. Method and apparatus for ultrafiltration utilizing a long peripheral access venous cannula for blood withdrawal
FR2827153A1 (en) 2001-07-12 2003-01-17 Younes Boudjemline Closure for cardiopathic septal faults has hollow discoid body with central constriction forming tube with one way valve
US20030036698A1 (en) * 2001-08-16 2003-02-20 Robert Kohler Interventional diagnostic catheter and a method for using a catheter to access artificial cardiac shunts
US6978176B2 (en) * 2001-12-08 2005-12-20 Lattouf Omar M Treatment for patient with congestive heart failure
US7318833B2 (en) 2001-12-19 2008-01-15 Nmt Medical, Inc. PFO closure device with flexible thrombogenic joint and improved dislodgement resistance
JP2005512687A (en) 2001-12-20 2005-05-12 トリバスキュラー,インコーポレイティド Method and apparatus for manufacturing intravascular graft section
US7699059B2 (en) 2002-01-22 2010-04-20 Cardiomems, Inc. Implantable wireless sensor
US7311690B2 (en) * 2002-02-25 2007-12-25 Novashunt Ag Implantable fluid management system for the removal of excess fluid
US6638257B2 (en) * 2002-03-01 2003-10-28 Aga Medical Corporation Intravascular flow restrictor
US7270675B2 (en) 2002-05-10 2007-09-18 Cordis Corporation Method of forming a tubular membrane on a structural frame
US7390310B2 (en) * 2002-07-10 2008-06-24 Codman & Shurtleff, Inc. Shunt valve locking mechanism
WO2004028348A3 (en) 2002-09-26 2004-06-17 Neal L Eigler Cardiovascular anchoring device and method of deploying same
US8303511B2 (en) 2002-09-26 2012-11-06 Pacesetter, Inc. Implantable pressure transducer system optimized for reduced thrombosis effect
US7608067B2 (en) 2002-11-06 2009-10-27 Aram Bonni Patient-adjustable incontinence device (AID)
US20030176914A1 (en) 2003-01-21 2003-09-18 Rabkin Dmitry J. Multi-segment modular stent and methods for manufacturing stents
US20040162514A1 (en) * 2003-02-14 2004-08-19 Scout Medical Technologies System and method for controlling differential pressure in a cardio-vascular system
EP2168536B1 (en) 2003-03-12 2016-04-27 Cook Medical Technologies LLC Prosthetic valve that permits retrograde flow
WO2004082528A3 (en) 2003-03-17 2005-08-11 Cook Inc Vascular valve with removable support component
US7967769B2 (en) 2003-04-08 2011-06-28 Rox Medical Inc. Implantable arterio-venous shunt devices and methods for their use
US20040267306A1 (en) 2003-04-11 2004-12-30 Velocimed, L.L.C. Closure devices, related delivery methods, and related methods of use
US7175656B2 (en) * 2003-04-18 2007-02-13 Alexander Khairkhahan Percutaneous transcatheter heart valve replacement
US7041127B2 (en) 2003-05-28 2006-05-09 Ledergerber Walter J Textured and drug eluting coronary artery stent
US7317951B2 (en) 2003-07-25 2008-01-08 Integrated Sensing Systems, Inc. Anchor for medical implant placement and method of manufacture
US20050165344A1 (en) * 2003-11-26 2005-07-28 Dobak John D.Iii Method and apparatus for treating heart failure
US7261732B2 (en) 2003-12-22 2007-08-28 Henri Justino Stent mounted valve
EP1771132A4 (en) 2004-02-03 2009-12-16 Atria Medical Inc Device and method for controlling in-vivo pressure
US7311730B2 (en) 2004-02-13 2007-12-25 Shlomo Gabbay Support apparatus and heart valve prosthesis for sutureless implantation
US7780725B2 (en) 2004-06-16 2010-08-24 Sadra Medical, Inc. Everting heart valve
CA2581677C (en) 2004-09-24 2014-07-29 Nmt Medical, Inc. Occluder device double securement system for delivery/recovery of such occluder device
US7794473B2 (en) 2004-11-12 2010-09-14 C.R. Bard, Inc. Filter delivery system
US7905901B2 (en) * 2004-11-29 2011-03-15 Cardia, Inc. Self-centering occlusion device
US8012198B2 (en) 2005-06-10 2011-09-06 Boston Scientific Scimed, Inc. Venous valve, system, and method
US20070213813A1 (en) 2005-12-22 2007-09-13 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
US9681948B2 (en) 2006-01-23 2017-06-20 V-Wave Ltd. Heart anchor device
US20120041422A1 (en) * 2006-02-03 2012-02-16 Pacesetter, Inc. System and method for manipulating insertion pathways for accessing target sites
EP1988851A2 (en) 2006-02-14 2008-11-12 Sadra Medical, Inc. Systems and methods for delivering a medical implant
US8876895B2 (en) 2006-09-19 2014-11-04 Medtronic Ventor Technologies Ltd. Valve fixation member having engagement arms
ES2378905T3 (en) 2006-10-10 2012-04-19 Celonova Biosciences, Inc. Heart valve bioprotà © music with polyphosphazene
JP2010508093A (en) 2006-11-07 2010-03-18 セラマジャー,デイヴィッド,スティーヴン Apparatus and method for treating heart failure
EP2129332A1 (en) 2007-02-16 2009-12-09 Medtronic, Inc. Replacement prosthetic heart valves and methods of implantation
EP2160140B1 (en) 2007-06-26 2014-11-05 Galit Avior Eustachian tube device
US8734483B2 (en) 2007-08-27 2014-05-27 Cook Medical Technologies Llc Spider PFO closure device
US7981151B2 (en) 2007-10-15 2011-07-19 Edwards Lifesciences Corporation Transcatheter heart valve with micro-anchors
CA2703665C (en) 2007-10-25 2016-05-10 Symetis Sa Stents, valved-stents and methods and systems for delivery thereof
US7806921B2 (en) 2007-11-08 2010-10-05 Cook Incorporated Monocusp valve design
US9138213B2 (en) 2008-03-07 2015-09-22 W.L. Gore & Associates, Inc. Heart occlusion devices
US20090276040A1 (en) 2008-05-01 2009-11-05 Edwards Lifesciences Corporation Device and method for replacing mitral valve
JP5002740B1 (en) * 2009-04-28 2012-08-15 ディーシー ディヴァイシーズ インコーポレイテッド Apparatus for treating heart failure, the system and method
EP2427143B1 (en) 2009-05-04 2017-08-02 V-Wave Ltd. Device for regulating pressure in a heart chamber
US20110054515A1 (en) 2009-08-25 2011-03-03 John Bridgeman Device and method for occluding the left atrial appendage
RU140821U1 (en) 2009-11-02 2014-05-20 Симетис Са Aortic bioprosthesis and systems for their delivery to the site of implantation
EP3335670A1 (en) 2010-03-05 2018-06-20 Edwards Lifesciences Corporation Retaining mechanisms for prosthetic valves
US8597225B2 (en) * 2010-07-26 2013-12-03 The Cleveland Clinic Foundation Method for increasing blood flow in or about a cardiac or other vascular or prosthetic structure to prevent thrombosis
US9034034B2 (en) 2010-12-22 2015-05-19 V-Wave Ltd. Devices for reducing left atrial pressure, and methods of making and using same
US9629715B2 (en) 2011-07-28 2017-04-25 V-Wave Ltd. Devices for reducing left atrial pressure having biodegradable constriction, and methods of making and using same
EP2999412A2 (en) 2013-05-21 2016-03-30 V-Wave Ltd. Apparatus for delivering devices for reducing left atrial pressure

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9232997B2 (en) 2006-11-07 2016-01-12 Corvia Medical, Inc. Devices and methods for retrievable intra-atrial implants
US8740962B2 (en) 2006-11-07 2014-06-03 Dc Devices, Inc. Prosthesis for retrieval and deployment
US8745845B2 (en) 2006-11-07 2014-06-10 Dc Devices, Inc. Methods for mounting a prosthesis onto a delivery device
US8752258B2 (en) 2006-11-07 2014-06-17 Dc Devices, Inc. Mounting tool for loading a prosthesis
US8882697B2 (en) 2006-11-07 2014-11-11 Dc Devices, Inc. Apparatus and methods to create and maintain an intra-atrial pressure relief opening
US9456812B2 (en) 2006-11-07 2016-10-04 Corvia Medical, Inc. Devices for retrieving a prosthesis
US9358371B2 (en) 2006-11-07 2016-06-07 Corvia Medical, Inc. Intra-atrial implants made of non-braided material
US8460372B2 (en) 2006-11-07 2013-06-11 Dc Devices, Inc. Prosthesis for reducing intra-cardiac pressure having an embolic filter
US10045766B2 (en) 2006-11-07 2018-08-14 Corvia Medical, Inc. Intra-atrial implants to directionally shunt blood
US9277995B2 (en) 2010-01-29 2016-03-08 Corvia Medical, Inc. Devices and methods for reducing venous pressure
US9205236B2 (en) 2011-12-22 2015-12-08 Corvia Medical, Inc. Methods, systems, and devices for resizable intra-atrial shunts
US8951223B2 (en) 2011-12-22 2015-02-10 Dc Devices, Inc. Methods and devices for intra-atrial shunts having adjustable sizes
US9642993B2 (en) 2011-12-22 2017-05-09 Corvia Medical, Inc. Methods and devices for intra-atrial shunts having selectable flow rates
US9005155B2 (en) 2012-02-03 2015-04-14 Dc Devices, Inc. Devices and methods for treating heart failure
US9649480B2 (en) 2012-07-06 2017-05-16 Corvia Medical, Inc. Devices and methods of treating or ameliorating diastolic heart failure through pulmonary valve intervention
US9775636B2 (en) 2013-03-12 2017-10-03 Corvia Medical, Inc. Devices, systems, and methods for treating heart failure

Also Published As

Publication number Publication date Type
US8091556B2 (en) 2012-01-10 grant
US20110218477A1 (en) 2011-09-08 application
US8235933B2 (en) 2012-08-07 grant
US20020173742A1 (en) 2002-11-21 application
US8328751B2 (en) 2012-12-11 grant
US20130197423A1 (en) 2013-08-01 application
US20140128796A1 (en) 2014-05-08 application
US20140128795A1 (en) 2014-05-08 application
US9943670B2 (en) 2018-04-17 grant

Similar Documents

Publication Publication Date Title
US7524331B2 (en) Catheter delivered valve having a barrier to provide an enhanced seal
US7011095B2 (en) Valve designs for left ventricular conduits
US7083588B1 (en) Apparatus for providing coronary retroperfusion and methods of use
US7381220B2 (en) Devices, systems, and methods for supplementing, repairing, or replacing a native heart valve leaflet
US6547821B1 (en) Surgical procedures and devices for increasing cardiac output of the heart
US7077801B2 (en) Methods and devices for improving cardiac output
US6887192B1 (en) Heart support to prevent ventricular remodeling
US20010044568A1 (en) Endoluminal ventricular retention
US20040015041A1 (en) Protective sheath apparatus and method for use with a heart wall actuation system for the natural heart
US20080039935A1 (en) Methods and apparatus for mitral valve repair
US4938766A (en) Prosthetic compliance devices
US6230714B1 (en) Cardiac constraint with prior venus occlusion methods
US20100076247A1 (en) Permanent ventricular assist device for treating heart failure
US20060030885A1 (en) Apparatuses and methods for heart valve repair
US6616684B1 (en) Endovascular splinting devices and methods
US20020111533A1 (en) Device and method for restructuring heart chamber geometry
US7186210B2 (en) In-vivo method and device for improving diastolic function of the left ventricle
US20060064059A1 (en) Treatment of infarct expansion by partially occluding vena cava
US20130138205A1 (en) Ventricular assist device and method
US20060252984A1 (en) Devices, systems, and methods for reshaping a heart valve annulus
US20050222488A1 (en) Devices, systems, and methods for reshaping a heart valve annulus
US6221103B1 (en) Device and method for restructuring heart chamber geometry
US20130030522A1 (en) Devices and methods for heart treatments
US7527646B2 (en) Devices, systems, and methods for retaining a native heart valve leaflet
US20120165928A1 (en) Devices for reducing left atrial pressure, and methods of making and using same

Legal Events

Date Code Title Description
AS Assignment

Owner name: LIBRA MEDICAL, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KESTEN, RANDY;KEREN, GAD;SIGNING DATES FROM 20010828 TO 20010911;REEL/FRAME:033563/0414

Owner name: V-WAVE LTD., ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ATRIA MEDICAL INC.;REEL/FRAME:033563/0773

Effective date: 20090915

Owner name: ATRIA MEDICAL INC., DELAWARE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LIBRA MEDICAL SYSTEMS INC.;REEL/FRAME:033563/0621

Effective date: 20040629

FPAY Fee payment

Year of fee payment: 4